Search

Displaying results 5921 - 5930 of 8974 in total
  1. Drug

    Amaranthus tuberculatus pollen

    go.drugbank.com/drugs/DB10497
    Approved

    Amaranthus tuberculatus pollen allergenic extract is used in allergenic testing.

    Mixtures: Number Four Weed Mixture
  2. Drug

    IMC-1C11

    go.drugbank.com/drugs/DB06101
    Experimental

    IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma.

  3. Drug

    JLK-247

    go.drugbank.com/drugs/DB17637
    Experimental

    JLK-247 is an adeno-associated viral vector serotype 9 (AAV9)-mediated gene replacement therapy for the treatment of Sanfilippo Syndrome Type C or MPS IIIC.[L46686]

  4. Drug

    Surovatamig

    go.drugbank.com/drugs/DB19420
    Investigational

    TNB-486 is under investigation in clinical trial NCT06564038 (A Study of AZD0486 Monotherapy or in Combination With Other Anti-cancer Agents for Mature B-cell Malignancies).

  5. Drug

    Ambrosia artemisiifolia pollen

    go.drugbank.com/drugs/DB10385
    Approved

    Ambrosia artemisiifolia pollen is the pollen of the Ambrosia artemisiifolia plant. Ambrosia artemisiifolia pollen is mainly used in allergenic testing.

  6. Drug

    Actinium Ac 225 dotatate

    go.drugbank.com/drugs/DB23632
    Investigational

    Actinium Ac 225 dotatate is under investigation in clinical trial NCT07150806 (RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma).

  7. Drug

    Tovecimig

    go.drugbank.com/drugs/DB30220
    Investigational

    NOV1501 is under investigation in clinical trial NCT03292783 (This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended

  8. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). … The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)).

  9. Target

    Folate receptor alpha

    go.drugbank.com/bio_entities/BE0003405
    TargetTransporterHumans

    Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release (PubMed:8567728). … Required for normal embryonic development and normal cell proliferation (By similarity)

    Synonyms: FOLR
  10. Drug

    SLx-4090

    go.drugbank.com/drugs/DB05678
    Investigational

    SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes. [A33218]